Literature DB >> 19475450

Involvement of CD40 targeting miR-224 and miR-486 on the progression of pancreatic ductal adenocarcinomas.

Soeren Torge Mees1, Wolf Arif Mardin, Sonja Sielker, Edith Willscher, Norbert Senninger, Christina Schleicher, Mario Colombo-Benkmann, Joerg Haier.   

Abstract

BACKGROUND: Genetic and epigenetic alterations during development of pancreatic ductal adenocarcinomas (PDAC) are well known. Genetic and epigenetic data were correlated with tumor biology to find specific alterations responsible for invasion and metastasis in pancreatic ductal adenocarcinomas.
METHODS: A total of 16 human PDAC cell lines were used in murine orthotopic PDAC models. By means of standardized dissemination scores, local invasion and metastatic spread were assessed. mRNA and microRNA expression were studied by microarray and TaqMan low-density array. Quantitative real-time-polymerase chain reaction and flow cytometry were used for expression validation.
RESULTS: CD40 was detected as a relevant target gene for differentially expressed miRNAs observed in highly invasive and metastatic PDAC only. A significant overexpression (P < .05) of CD40-related miRNAs miR-224 and miR-486 was detected in highly invasive and metastatic PDAC, whereas CD40 mRNA expression was not significantly altered. Instead, CD40 protein expression at cell surfaces of these highly invasive and metastatic PDAC was significantly reduced (P < .01).
CONCLUSIONS: Epigenetic alterations with upregulated CD40-targeting miR-224 and miR-486 are related to downregulated CD40 protein expression at cell surfaces in highly invasive and metastatic PDAC. Thus, miRNA-regulated CD40 expression seems to play an important role in progression of PDAC. These data suggest a diagnostic and therapeutic potential for CD40 and/or its targeting miRNAs in PDAC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19475450     DOI: 10.1245/s10434-009-0531-4

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  56 in total

Review 1.  Prospects of miRNA-based therapy for pancreatic cancer.

Authors:  Priya Pai; Satyanarayana Rachagani; Chandrakanth Are; Surinder K Batra
Journal:  Curr Drug Targets       Date:  2013-09       Impact factor: 3.465

Review 2.  Metastamirs: a stepping stone towards improved cancer management.

Authors:  Nicole M A White; Eman Fatoohi; Maged Metias; Klaus Jung; Carsten Stephan; George M Yousef
Journal:  Nat Rev Clin Oncol       Date:  2010-11-02       Impact factor: 66.675

Review 3.  Targeting microRNAs in pancreatic cancer: microplayers in the big game.

Authors:  Sheema Khan; Deepak Kumar; Meena Jaggi; Subhash C Chauhan
Journal:  Cancer Res       Date:  2013-11-07       Impact factor: 12.701

4.  Differential expression of miR-139, miR-486 and miR-21 in breast cancer patients sub-classified according to lymph node status.

Authors:  Lene Rask; Eva Balslev; Rolf Søkilde; Estrid Høgdall; Henrik Flyger; Jens Eriksen; Thomas Litman
Journal:  Cell Oncol (Dordr)       Date:  2014-07-16       Impact factor: 6.730

5.  Therapy-, gender- and race-specific microRNA markers, target genes and networks related to glioblastoma recurrence and survival.

Authors:  K R Delfino; N V L Serão; B R Southey; S L Rodriguez-Zas
Journal:  Cancer Genomics Proteomics       Date:  2011 Jul-Aug       Impact factor: 4.069

6.  Glyceollins as novel targeted therapeutic for the treatment of triple-negative breast cancer.

Authors:  Lyndsay V Rhodes; Syreeta L Tilghman; Stephen M Boue; Shuchun Wang; Hafez Khalili; Shannon E Muir; Melyssa R Bratton; Qiang Zhang; Guangdi Wang; Matthew E Burow; Bridgette M Collins-Burow
Journal:  Oncol Lett       Date:  2011-10-24       Impact factor: 2.967

Review 7.  MicroRNAs (miRNAs) in cancer invasion and metastasis: therapeutic approaches based on metastasis-related miRNAs.

Authors:  Achim Aigner
Journal:  J Mol Med (Berl)       Date:  2011-01-14       Impact factor: 4.599

8.  Upregulated microRNA-224 promotes ovarian cancer cell proliferation by targeting KLLN.

Authors:  Ke Hu; Meng Liang
Journal:  In Vitro Cell Dev Biol Anim       Date:  2016-09-23       Impact factor: 2.416

9.  Three dysregulated miRNAs control kallikrein 10 expression and cell proliferation in ovarian cancer.

Authors:  N M A White; T-F F Chow; S Mejia-Guerrero; M Diamandis; Y Rofael; H Faragalla; M Mankaruous; M Gabril; A Girgis; G M Yousef
Journal:  Br J Cancer       Date:  2010-03-30       Impact factor: 7.640

10.  Identification of circulating microRNAs in HNF1A-MODY carriers.

Authors:  C Bonner; K C Nyhan; S Bacon; M P Kyithar; J Schmid; C G Concannon; I M Bray; R L Stallings; J H M Prehn; M M Byrne
Journal:  Diabetologia       Date:  2013-05-15       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.